mRNA Raw Materials

In vitro synthesis of RNA is catalyzed by bacteriophage (SP6, T7 or T3) RNA polymerases using linear DNA as a template. Ribonucleoside triphosphates (NTPs) are the building blocks of these in vitro transcription reactions. Some naturally occuring RNAs such as messenger RNAs (mRNAs) or long non-coding RNAs (lncRNAs) contain a variety of modifications e.g. 5'-end guanosinemethylation (5'-Cap), 3'-end adenosine (poly(A) tail or several internal base modifications which markedly influence their biological function (e.g. translation efficiency, stability or immunogenicity). These structural features can be introduced during in vitro transcription via correspondingly modified NTPs and cap analoga to obtain biologically functional synthetic RNAs.

The SARS-CoV-2 pandemic has thrust mRNA therapeutics into the spotlight. From vaccines and immunotherapy to protein replacement and cell reprogramming, scientists' interest in mRNA manufacturing has exploded. Accelerated development of mRNA-based vaccines requires the conversion of standard research-grade in vitro transcription reagents into raw materials specifically designed and manufactured to advanced quality standards. As a global raw material supplier for mRNA, Creative Biogene helps you strengthen your supply chain, simplify the transition to manufacturing, ensure continuous production, and create consistently high-quality products.

The key to successful mRNA therapy starts with high-quality starting materials: mRNA reagents at a glance.